Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol's Poker Game: Doubling Down On Research

This article was originally published in The Pink Sheet Daily

Executive Summary

Medarex acquisition has interesting strategic parallels with the earlier Amgen/Abgenix deal, and demonstrates once again Bristol's distinctive approach of doubling down on research rather than protecting itself through diversification toward slower growth businesses.
Advertisement

Related Content

Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
Bristol-Myers Squibb Buys Medarex: Adds Eighth ‘Pearl' To String
KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
KRAS Testing Gets On Label Of EGFr Products; Will Tests Get To Clinic Soon?
Why Doesn't Pharma Get Smaller?
Why Doesn't Pharma Get Smaller?
Amgen/Abgenix: All About a Drug
Amgen/Abgenix: All About a Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS069735

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel